In this Circulation on the Run transcript episode, Marcely Bonatto and Torbjørn Omland discuss the SARAH Trial , a double-blind, randomized, placebo-controlled study testing whether sacubitril–valsartan can prevent anthracycline-induced cardiotoxicity in patients who develop elevated cardiac troponin I during chemotherapy. The conversation explores trial design, timing and selection of high-risk patients based on troponin rise, and key efficacy and safety signals related to left ventricular function preservation and biomarker trajectories. The episode also places SARAH in the broader context of cardio-oncology, highlighting how early neurohormonal blockade might modify the trajectory of chemotherapy-related cardiac dysfunction for selected patients .
Listen to this episode as Dr. Bonatto walks us through the SARAH Trial , exploring how sacubitril–valsartan may protect a high‑risk…
